Medicine and Dentistry
Adenocarcinoma
8%
Adverse Event
11%
Arm
10%
Biological Marker
13%
Biopsy Technique
12%
Cancer
31%
Cancer Staging
20%
Cardiac Magnetic Resonance Imaging
7%
Chemoradiotherapy
13%
Chest
13%
Circulating Tumor DNA
8%
Clinical Trial
8%
Computer Assisted Tomography
36%
COVID-19
15%
Diagnosis
14%
Diagnostic Imaging
9%
Differential Diagnosis
7%
Diseases
34%
Epidermal Growth Factor Receptor
6%
Epithelioma
5%
Esophageal Cancer
7%
Esophagus Carcinoma
5%
Hazard Ratio
7%
Health Care
6%
Immune Checkpoint Inhibitor
18%
Immune System
5%
Immunity
12%
Immunotherapy
25%
Infection
5%
Intensity Modulated Radiation Therapy
5%
Ipilimumab
10%
Lobectomy
5%
Low Drug Dose
11%
Lung
36%
Lung Adenocarcinoma
7%
Lung Cancer
71%
Lung Cancer Screening
12%
Lung Metastasis
11%
Lung Nodule
16%
Lymph Node
6%
Magnetic Resonance Imaging
19%
Malignant Neoplasm
37%
Mediastinum Mass
13%
Metastatic Carcinoma
30%
Neoplasm
100%
Neuroendocrine Tumor
6%
Nivolumab
9%
Non Small Cell Lung Cancer
46%
Non-Small Cell Lung Cancer
5%
Odds Ratio
6%
Oncology
8%
Overall Survival
17%
Pembrolizumab
10%
Phase II Trials
8%
Pleura Mesothelioma
7%
Pneumonia
15%
Polyethylene Terephthalate
9%
Positron Emission Tomography-Computed Tomography
23%
Progression Free Survival
12%
Pulmonary Embolism
14%
Radiation Therapy
39%
Radiology
30%
Randomized Clinical Trial
7%
Recurrent Disease
13%
Selinexor
8%
Solid Malignant Neoplasm
8%
Stereotactic Body Radiation Therapy
8%
Surgery
14%
Systemic Therapy
5%
Targeted Therapy
11%
Thoracic Wall
6%
Thorax Radiography
13%
Thymic Carcinoma
10%
Thymus Cancer
11%
Venous Thromboembolism
7%
Keyphrases
Abscopal Response
5%
ACR Appropriateness Criteria
10%
Adenocarcinoma
9%
Advanced or Metastatic
6%
Advanced Solid Tumors
13%
Artificial Intelligence
6%
Artificial Intelligence Ethics
6%
Artificial Intelligence in Radiology
6%
Cancer Mortality
5%
Cancer Patients
9%
Carboplatin
8%
Chemoradiation
6%
Chemotherapy
12%
Circulating Tumor DNA (ctDNA)
6%
Clinical Activity
5%
Clinical Outcomes
9%
Computed Tomography
13%
Confidence Interval
14%
Differential Diagnosis
5%
Early-stage Lung Cancer
5%
Esophageal Cancer
7%
European American
6%
Hazard Ratio
9%
Imaging Appearance
6%
Imaging Findings
7%
Imaging Modalities
6%
Immune Checkpoint Inhibitors
17%
In Cancer
12%
International Association for the Study of Lung Cancer (IASLC)
12%
International Thymic Malignancy Interest Group (ITMIG)
7%
Ipilimumab
10%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Low-dose Radiation
6%
Lung
10%
Lung Cancer
40%
Lung Cancer Screening
9%
Lung Cancer Staging
12%
Magnetic Resonance Imaging
8%
Malignancy
5%
Median Overall Survival
5%
Median Progression-free Survival
7%
Mediastinal Compartments
5%
Mediastinal Mass
8%
Metastatic Disease
8%
Metastatic Tumor
8%
Misinterpretation
8%
Multi-arm
13%
Neoplasms
6%
Ninth Edition
10%
Nivolumab
8%
Non-small Cell Lung Cancer (NSCLC)
33%
Non-small Cell Lung Cancer Patients
5%
North America
7%
Objective Response Rate
6%
Overall Survival
14%
Paclitaxel
6%
Partial Response
6%
Pearl
12%
Pembrolizumab
7%
Phase Ib Study
10%
Phase II Study
10%
Phase II Trial
10%
Pneumonitis
13%
Positron Emission Tomography-computed Tomography (PET-CT)
16%
Programmed Death-ligand 1 (PD-L1)
12%
Progression-free Survival
9%
Pulmonary Embolism
6%
Radiation Therapy
10%
Radiologists
14%
Radiology
5%
Radiotherapy
8%
Randomized Clinical Trial
6%
Selinexor
14%
Single Center
13%
Stereotactic Ablative Radiotherapy
6%
Stereotactic Body Radiation Therapy
7%
Symptomatic Pulmonary Embolism
7%
Systemic Therapy
5%
Targeted Immunotherapy
5%
Targeted Therapy
11%
Thorax
9%
Thymic Carcinoma
8%
Thymic Epithelial Tumors
6%
TNM Classification
7%
Treatment-related Adverse Events
6%
Tumor
42%
Tumor-node-metastasis Staging
5%